Wegovy Prescription Dosage: What the Clinical Evidence Shows

What the STEP 1 trial tells us about dose and outcome

The evidence behind Wegovy's dosing schedule starts with the STEP 1 trial, published in the New England Journal of Medicine, which followed 1,961 adults with obesity over 68 weeks. Participants who reached and maintained the 2.4 mg weekly dose achieved an average body-weight reduction of around 15%, compared with roughly 2.4% in those on placebo alongside the same lifestyle support. That gap is substantial, and it's the foundation the MHRA and NICE used when evaluating the medicine.

What the trial also showed is that the slow titration matters. Participants moved through each dose step over approximately four weeks, giving the body time to adjust to semaglutide's effects on appetite and gastric emptying. Rushing that process increases the likelihood of nausea and other gastrointestinal side effects, which is precisely why the schedule exists. A common assumption is that a higher dose sooner means faster results; the evidence doesn't bear that out, and it tends to increase the chance of side effects that prompt people to stop treatment early.

Since STEP 1, the programme has expanded. The MHRA approved a single-dose 7.2 mg pen in April 2026, following trial data reporting approximately 20.7% average weight loss over 72 weeks at that maintenance dose, narrowing the gap with tirzepatide. The titration principle remains the same: you begin at 0.25 mg regardless of which maintenance dose you're working towards, and each increase is a clinical decision, not a fixed calendar event.

How prescribers decide when to move your dose up

The step from one dose to the next isn't automatic. A prescriber reviews how you've tolerated the current dose before recommending an increase, checking for side effects, any concerns about injection technique, and your overall progress. This is why understanding Wegovy's order of dosage is useful before you start: knowing what to expect at each rung helps you report back accurately.

At nume, a GPhC-registered Independent Prescriber reads your repeat request personally before any dose change is issued. There is no automated escalation. Patients who experience persistent nausea or other GI symptoms may be asked to stay at their current dose for longer than four weeks, that's not a failure; it's how the medicine is meant to be used safely. Requests to skip a step or increase faster than the schedule allows are assessed individually and, where clinically appropriate, declined.

One thing worth knowing: if you reach the highest tolerated dose and haven't lost at least 5% of your body weight after six months, NICE guidance (TA875) advises that continuing should be reviewed. Your prescriber is best placed to weigh that up alongside everything else they know about your health.

Eligibility and what the licensed indications cover

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition, such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. The 7.2 mg pen approved in April 2026 carries a narrower licence: BMI ≥30 only, not for those in the 27–29.9 bracket. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. People with a personal or family history of medullary thyroid carcinoma, or certain gastrointestinal conditions, will need a careful prescriber assessment before starting. If you are considering how to get a Wegovy prescription, a full clinical assessment is the first step, not a formality, but the point at which all of these factors are weighed properly.

It is also worth noting that Wegovy and Ozempic both contain semaglutide, but Ozempic is licensed for type 2 diabetes management, not weight loss. The dosing schedules differ, and they are not interchangeable.

Getting the prescription through a regulated online pharmacy

For people who don't meet NHS criteria or prefer not to join a waiting list, a private prescription route is the legal alternative, and those wondering whether non-prescription Wegovy is an option should be aware that no legitimate route exists without a proper clinical assessment. You can read more about the cost of Wegovy through a private service and what a legitimate price should include. The key point on any route is that the prescription must come from a clinician who has properly assessed you, not from a seller offering the medicine without one. The MHRA has warned repeatedly about counterfeit and unlicensed weight-loss pens circulating online; verifying any pharmacy on the GPhC register before placing an order is a straightforward safety step.

If you'd like to know more about how the private prescription process works from start to finish, the Wegovy prescription online page covers the regulated route in detail. Treatment through nume begins with a free consultation, reviewed the same day by a prescriber. There are no subscriptions and no automated renewals, each repeat is assessed individually, including any proposed dose increase. When you feel ready to take the next step, you can check your eligibility through our free consultation.